Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Accurate detection of low prevalence AKT1 E17K mutation in tissue or plasma from advanced cancer patients.

PloS one - 1 Jan 2017

de Bruin Elza C, Whiteley Jessica L, Corcoran Claire, Kirk Pauline M, Fox Jayne C, Armisen Javier, Lindemann Justin P O, Schiavon Gaia, Ambrose Helen J, Kohlmann Alexander

Abstract excerpt

Personalized healthcare relies on accurate companion diagnostic assays that enable the most appropriate treatment decision for cancer patients. Extensive assay validation prior to use in a clinical setting is essential for providing a reliable test result. This poses a challenge for low prevalence mutations with limited availability of appropriate clinical samples harboring the mutation. To enable prospective...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to AKT1 gene
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasms

Share to Paraffin Embedding

Share to Polymerase Chain Reaction

Share to Proto-Oncogene Proteins c-akt

Share to Reference Standards

Share to Reproducibility of Results

Source

Open in PubMed Open full text

Identifiers

PMID: 28472036
DOI: 10.1371/journal.pone.0175779
PMCID: PMC5417426

Genes

AKT1

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Accurate detection of low prevalence AKT1 E17K mutation in tissue or plasma from advanced cancer patients.PMID 28472036Read ↗

AKT1 (E17K) mutation profiling in breast cancer: prevalence, concurrent oncogenic alterations, and blood-based detection.Semantic proximity Read ↗

Utility of Serial cfDNA NGS for Prospective Genomic Analysis of Patients on a Phase I Basket Study.Semantic proximity Read ↗

Retrospective comparison between breast cancer tissue- and blood-based next-generation sequencing results in detection of PIK3CA, AKT1, and PTEN alterationsSemantic proximity Read ↗

AKT Inhibition in Solid Tumors With AKT1 Mutations.Semantic proximity Read ↗

Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias.Semantic proximity Read ↗

Recurrent AKT mutations in human cancers: functional consequences and effects on drug sensitivity.Semantic proximity Read ↗

Characteristics and Outcome of AKT1 E17K-Mutant Breast Cancer Defined through AACR Project GENIE, a Clinicogenomic Registry.Semantic proximity Read ↗

Mutation detection by real-time PCR: a simple, robust and highly selective method.Semantic proximity Read ↗

ESR1 ctDNA testing: literature review and comparison of assays for ESR1 mutation detection in advanced hormone receptor-positive breast cancer.Semantic proximity Read ↗

Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1 E17K-Mutant, ER-Positive Metastatic Breast Cancer.Semantic proximity Read ↗

Standardized Analytical Verification of ctDNA ESR1 Mutation Testing in Metastatic HR+/HER2- Breast Cancer: A European Multicentre Study Using dPCR and NGS-Based Liquid Biopsy.Semantic proximity Read ↗

Patient with Lobular Carcinoma of the Breast and Activating AKT1 E17K Variant.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.